Science workshop

In December 2021, the FDA approved injectable cabotegravir as PrEP (CAB PrEP; brand name Apretude). As the first injectable form of HIV PrEP, CAB PrEP is a much-needed addition to an expanding array of prevention options. To ensure that this option transforms into real choice, stakeholders must have a good understanding of barriers to roll out, solutions to overcome them and strategies to address and avoid pitfalls associated with early introduction of oral PrEP. This workshop will explore what is needed to ensure that introductory research and programmes are strategically designed, user-centred and appropriately resourced to support successful roll out of CAB PrEP. The workshop will be co-convened by MOSAIC and WHO in partnership with EpiC, RISE, CASPR and BioPIC.